At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
SYN111 +1 moredrug
Likely dose
SYN111 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder
In Brief
A Phase 2 clinical trial evaluating SYN111 and Placebo for Generalized Anxiety Disorder. Completed, enrolled 239 participants across 2 sites.
Detailed Summary
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
CollaboratorsSyneos Health
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartMar 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartMar 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.5 years ago
Interventions
SYN111drug
500 mg for 1 week followed by 1000 mg for 7 weeks
Placebodrug
0 mg tablets